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Throughout the past years we stepwise modified our immunosuppressive treatment regimen for patients with antibody-mediated
rejection (ABMR). Here, we describe three consecutive groups treated with different regimens. From 2005 until 2008, we treated
all patients with biopsy-proven ABMR with rituximab (500mg), low-dose (30 g) intravenous immunoglobulins (IVIG), and
plasmapheresis (PPH, 6x) (group RLP, 𝑛 = 12). Between 2009 and June 2010, patients received bortezomib (1.3mg/m2, 4x) together
with low-dose IVIG and PPH (group BLP, 𝑛 = 11). In July 2010, we increased the IVIG dose and treated all subsequent patients with
bortezomib, high-dose IVIG (1.5 g/kg), and PPH (group BHP, 𝑛 = 11). Graft survival at three years after treatment was 73% in group
BHPas compared to 45% in groupBLP and 25% in groupRLP.At sixmonths after treatmentmedian serumcreatininewas 2.1 mg/dL,
2.9mg/dL, and 4.2mg/dL in groups BHP, BLP, and RLP, respectively (𝑝 = 0.02). Following treatment, a significant decrease of
donor-specific HLA antibody (DSA) mean fluorescence intensity from 8467 ± 6876 to 5221 ± 4711 (𝑝 = 0.01) was observed in
group BHP, but not in the other groups. Our results indicate that graft survival, graft function, and DSA levels could be improved
along with stepwise modifications to our treatment regimen, that is, the introduction of bortezomib and high-dose IVIG treatment.
1. Introduction
Antibody-mediated rejection (ABMR) is one of the most
challenging complications following renal transplantation.
Paul Terasaki proposed in his humoral theory of transplanta-
tion that the majority of transplants are rejected by the action
of antibodies, not cells [1]. In a cross-sectional study, we
were able to show that about 30% of patients may have HLA
antibodies (HLAab) after transplantation [2]. In more than
30%ofHLAab positive patients donor-specificHLAab (DSA)
were present. Renal allograft survival at 5.5 years after HLAab
testing was significantly lower in patients with detectable
DSA as compared to HLAab negative patients (49% versus
83%). In a series of 60 patients Sellare´s et al. observed
that graft failure was caused by ABMR in the majority of
cases [3]. To date, plasmapheresis (PPH) together with the
application of intravenous immunoglobulins (IVIG) has been
the mainstay of ABMR treatment [4, 5]. Over the last years
monoclonal antibodies directed against B cells (rituximab)
as well as inhibitors of the proteasome (bortezomib) have
expanded our therapeutic repertoire [6]. In a previous retro-
spective analysis, we observed a trend towards an improved
graft survival in patients treated with a combination of
bortezomib (1.3mg/m2, 4x), low-dose IVIG (30 g), and PPH
(6x) as compared to patients treated with the same regimen
but a fixed dose of rituximab (500mg) instead of bortezomib
[7]. However, even the bortezomib-based regimen was not
sufficient to treat all episodes of ABMR effectively.
IVIG preparations containing the pooled serum IgG
fractions from thousands of donors have been used for
treatment of various autoimmune diseases for more than 30
years. Usually, low doses of IVIG (0.1–0.2 g/kg) are used to
substitute immunoglobulins (“replacement”) in patients with
inherited hypogammaglobulinaemia or following removal
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of immunoglobulins by PPH. Pursuing immunomodulation
higher doses (“therapeutic”) are necessary (1-2 g/kg). Mech-
anistically, the effects of IVIG on the immune system can be
differentiated into effects mediated by the dimeric antigen-
binding [F(ab󸀠)2] fragment and the Fc fragment [8]. F(ab
󸀠)2-
dependent mechanisms include neutralization of pathologic
antibodies (anti-idiotypic) and cytokines, depletion of neu-
trophils and eosinophils, scavenging of anaphylatoxins such
as C3a and C5a, and blockade of cellular receptors. More
recent research has shown that much of the immunosup-
pressive effect of IVIG is mediated via the Fc fragment
[8]. These effects include upregulation of the inhibitory
Fc𝛾 receptor Fc𝛾RIIB, downregulation of activating Fc𝛾
receptors, reduction of antibody half-life by competition
of IVIGs with pathological antibodies for binding to the
neonatal Fc receptor which recycles IgG, and expansion of
regulatory T-cells. Interestingly, Fc fragment glycosylation
including terminal sialic acid residues seems to be crucial
for the effectiveness of IVIG [9]. The fact that this important
structure is present only in a minority of the total serum IgG
pool [9] explains why high doses of IVIG are necessary to
achieve therapeutic efficacy.
Based on the abovementioned evidence on the dosage
and the underlying mechanism of action of IVIG, we
increased the applied IVIG dose from a low-dose (30 g fixed
dose) to a high-dose regimen (1.5 g/kg) in July 2010, in order
to further improve the efficacy of our bortezomib-based
treatment protocol. Here, we report on the long-term efficacy
and safety of treatment with bortezomib, high-dose IVIG,
and PPH (group BHP). The obtained results are compared
with two preceding groups of patients treated either with
rituximab, low-dose IVIG, and PPH (group RLP) or with
bortezomib, low-dose IVIG, and PPH (group BLP).
2. Patients and Methods
Between January 2005 and November 2008 nine consecutive
patients with biopsy-proven ABMR were treated with a
fixed dose of rituximab (500mg i.v.), six sessions of PPH
(2.5 L/session, 4% albumin), and low-dose (30 g) polyvalent
human IVIG (KIOVIG) after the last PPH (group RLP).
Since 2009, all of our patients with a diagnosis of ABMR
have received bortezomib-based treatment. However, three
patients received rituximab between 2010 and 2013 because
of a diagnosis of preexisting polyneuropathy, which is a well-
known side effect and consequently a contraindication for
bortezomib treatment. Therefore, group RLP finally com-
prised 12 patients. Between January 2009 and June 2010
eleven consecutive patients received bortezomib (1.3mg/m2
i.v., days 1, 4, 8, and 11), PPH (6x), and low-dose (30 g)
IVIG (group BLP). In July 2010 we increased the IVIG dose
and treated 11 consecutive patients with bortezomib, PPH
(6x), and high-dose (1.5 g/kg) IVIG (group BHP). In order
to avoid removal of rituximab and/or IVIG by means of
PPH, rituximab was given one day after the last PPH. IVIG
treatment was started two days after rituximab, in order to
reduce potential adverse interactions between IVIG and rit-
uximab. In addition, we monitored CD19+ peripheral B cells
following the administration of rituximab. CD19+ B cells were
either not measurable or slightly above the detection limit
following rituximab treatment [0.01/nL (0.00–0.01); normal
range 0.1–0.4/nL]. Patients of all groups additionally received
a three-day pulse of methylprednisolone (500mg/day i.v.).
After discharge all patients were regularly monitored in our
outpatient clinic.
Renal transplantation was performed at the Charite´ Hos-
pital based on a negative complement-dependent cytotoxicity
crossmatch (CDC-XM)with andwithout dithiothreitol using
T- and B-lymphocytes with current and historical serum.
In addition, graft allocation was based on a negative virtual
crossmatch by considering current and historical unaccept-
able antigens as defined by Luminex based single antigen
bead assays. Based on this procedure, none of the patients
underwent any kind of desensitization before transplanta-
tion. Consequently, only patients with de novo DSA were
included.
Altogether, 76% (26/34) of all patients received induction
therapy with either basiliximab (𝑛 = 22) or daclizumab (𝑛 =
4). The remaining eight patients were transplanted before the
introduction of basiliximab or daclizumab and received no
induction therapy. The distribution of patients, who received
no induction therapy, was not significantly different between
groups (group RLP 𝑛 = 4/12, group BLP 𝑛 = 3/11, and group
BHP 𝑛 = 1/11, 𝑝 = 0.37).
Renal biopsies were taken on indication only. All patients
presented with clinically relevant allograft dysfunction after
transplant manifesting as an otherwise unexplained increase
of serum creatinine (≥0.3mg/dL), proteinuria (≥1 g/d), or
primary nonfunction in the early phase after transplantation.
The diagnosis of ABMR was based on the presence of
circulatingDSA and significant allograft pathology according
to the definitions of the Banff classification [10]. C4d stain-
ing was done by indirect immunofluorescence on paraffin
sections using a polyclonal rabbit anti-human C4d IgG
antibody (Biomedica, Vienna, Austria). Only patients who
gave their written informed consent were considered eligible
for enrollment. All patients were treated in accordance with
the Declaration of Helsinki.
Serum samples before and after treatment were screened
for HLA antibodies (HLAab) by the Luminex bead-based
assay LABScreen Mixed (One Lambda, Canoga Park, CA,
USA). In addition, HLAab specificities were determined by
LABScreen Single Antigen beads assay (One Lambda). As
an indicator for the antibody level, the normalized MFI was
used. HLAab were considered positive when exceeding an
MFI value of 500. The DSA showing the highest MFI at the
time of ABMR diagnosis (DSAmax) and the MFI sum of all
DSA (DSAsum) were tracked to indicate the effectiveness of
treatment.
End of follow-up was June 30th, 2016. Renal allograft
survival was defined as the interval between diagnosis of
ABMR and return to maintenance dialysis treatment or
end of follow-up. The estimated glomerular filtration rate
(eGFR) was calculated according to the chronic kidney
disease epidemiology collaboration (CKD-EPI) formula [11].
All adverse events, abnormal laboratory values, and hospital-
izations were tracked from our web-based electronic patient
record system “TBase” [12]. Adverse events occurring during
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(𝑛 = 11) 𝑝
First/repeat transplantation 8/4 7/4 11/0 n.s.
Donor age 52.4 ± 13.8 42.3 ± 14.9 52.1 ± 15.2 n.s.
Living/deceased donor 5/7 5/6 7/4 n.s.
Interval between transplantation and diagnosis (months) 34.6 ± 56.9 58.1 ± 51.4 46.1 ± 44.7 n.s.
Early/late antibody-mediated rejection 6/6 2/9 2/9 n.s.
Pathology scoring
Glomerulitis (g) 0.8 ± 1.1 0.9 ± 1.0 1.6 ± 1.2 n.s.
Peritubular capillaritis (ptc) 1.1 ± 1.1 0.8 ± 1.1 1.5 ± 1.0 n.s.
Intimal arteritis (v) 0.7 ± 0.9 0.3 ± 0.6 0.5 ± 0.7 n.s.
Transplant glomerulopathy (cg) 1.1 ± 1.2 2.2 ± 1.3 0.8 ± 1.3 0.049 (BLP versusBHP)
C4d (immunohistochemistry) 1.4 ± 1.3 2.0 ± 1.1 1.3 ± 1.3 n.s.
IVIG dose (g) 30 30 120 (80–150)
<0.001 (BHP versus
RLP and BHP versus
BLP)
Maintenance immunosuppression after diagnosis
Steroids 12 11 11 n.s.
Cyclosporine A 0 3 1 n.s.
Tacrolimus 12 6 10 0.01 (RLP versus BLP)
Everolimus 0 2 0 n.s.
Mycophenolic acid 12 11 11 n.s.




Group RLP, rituximab + low-dose IVIG + plasmapheresis; group BLP, bortezomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose
IVIG + plasmapheresis. IVIG, intravenous immunoglobulin. Comparison between groups was carried out using Fisher’s exact test for categorical variables and
Kruskal-Wallis test with Dunn-Bonferroni post hoc test for continuous variables.
the first year after treatment were documented and graded
according to the Common Terminology Criteria for Adverse
Events (CTCAE) version 3.0 [13]. Normally distributed vari-
ables are summarized as mean ± standard deviation. Not
normally distributed variables are summarized as median
and interquartile ranges. Comparison between groups was
carried out using Fisher’s exact test for categorical variables
and Kruskal-Wallis test with Dunn-Bonferroni post hoc test
for continuous variables.Wilcoxon signed-rank test was used
for pairwise comparison between different time points. Graft
survival was analyzed according to Kaplan-Meier with a log-
rank test. A multivariate Cox proportional hazard model was
used to identify covariates which independently contribute
to allograft loss following ABMR treatment. A probability
of less than 0.05 was considered as statistically significant.
Statistical analysis was carried out using IBM SPSS Statistics
for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA),
and STATA 11 IC software (StataCorp., College Station, TX,
USA).
3. Results
Relevant patient characteristics are shown in Table 1. The
interval between transplantation and diagnosis was not
different between groups. In all groups there were patients
with “early” ABMR occurring during the first year after
transplantation and patients with “late” ABMR. Scoring of
renal allograft tissue according to the Banff classification
revealed no differences between groups except for the trans-
plant glomerulopathy (cg) score, which was higher in group
BLP as compared to group BHP (2.2 ± 1.3 versus 0.8 ± 1.3,
𝑝 = 0.049). The applied IVIG dose for group BHP on
average was four times as high as that of both other groups
[120 g (range: 80–150 g) versus 30 g, 𝑝 < 0.001]. Follow-
ing diagnosis, all patients received triple drug maintenance
immunosuppression comprising a calcineurin inhibitor or
mammalian target of rapamycin inhibitor in combination
with steroids and mycophenolic acid. In group RLP more
patients received tacrolimus as compared to groupBLP (100%
versus 55%, 𝑝 = 0.01). Median observation time following
diagnosis was 101, 88, and 64 months for groups RLP, BLP,
and BHP, respectively. Due to the sequential nature of our
treatment protocol modifications follow-up was shortest for
the BHP group.
None of the patients died with a functioning graft.
Graft survival following diagnosis improved stepwise in the
three groups along with the sequential modifications of our
treatment protocol, that is, the substitution of rituximab by




























Figure 1: Graft survival according to Kaplan-Meier. Differences
between groups were calculated by log-rank test. Note: none of the
patients died with a functioning allograft. Group RLP, rituximab +
low-dose IVIG + plasmapheresis; group BLP, bortezomib + low-
dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose
IVIG + plasmapheresis. “+”, end of follow-up.
bortezomib (group RLP → BLP) and the increase of the
IVIG dose from a low-dose (30 g fixed dose) to a high-dose
(1.5 g/kg) IVIG regimen (group BLP → BHP) (Figure 1). A
significant difference in graft survival was observed between
group BHP and group RLP (𝑝 = 0.003). Graft survival at one
and three years after treatment was 91% and 73% in group
BHP, as compared to 55% and 45% in group BLP and 33% and
25% in group RLP, respectively. At the end of follow-up, graft
survival was 55% (6/11) in group BHP, 18% (2/11) in group
BLP, and 8% (1/12) in group RLP. At diagnosis, serum crea-
tinine [2.7mg/dL (1.9–2.9) versus 2.9mg/dL (2.6–4.1) versus
3.0mg/dL (2.6–3.0), 𝑝 = 0.23] (Figure 2) and proteinuria
[1.3 g/d (0.5–2.1) versus 1.1 g/d (0.45–3.9) versus 0.9 g/d (0.5–
1.8), 𝑝 = 0.79] (Figure 3) were not significantly different
between groups BHP, BLP, and RLP, respectively. Following
treatment, serum creatinine was lower in group BHP as
compared to both other groups (Figure 2). A significant
difference of groupBHPas compared to groupBLP and group
RLP was observed at six months after treatment [2.1mg/dL
(1.6–2.3) versus 2.9mg/dL (2.7–3.8) versus 4.2mg/dL (2.9–
4.6), 𝑝 = 0.02] (Figure 2). In accordance, eGFR at six months
after diagnosis was higher in group BHP as compared to
both other groups [33.0mL/min/1.73m2 (26.9–41.4) versus
26.0mL/min/1.73m2 (15.5–32.0) versus 16.3mL/min/1.73m2
(15.4–19.0), 𝑝 = 0.03]. In addition, proteinuria was signifi-
cantly lower in group BHP as compared to both other groups
at six months after diagnosis [0.15 g/d (0.1–0.4) versus 1.2 g/d
(1.0–2.1) versus 1.2 g/d (0.7–2.4), 𝑝 = 0.049] (Figure 3).
The immunological characteristics with respect to HLA
mismatches and HLA antibodies are summarized in Table 2.
The count of HLA class I and II mismatches was equally
distributed between groups. Similarly, HLA antibody panel
reactivity (% PRA) at the time of diagnosis did not differ









































































Figure 2: Serum creatinine before, during, and after treatment of
antibody-mediated rejection of all patients with a functioning graft
at each time point. Differences between groups were calculated by
Kruskal-Wallis test withDunn-Bonferroni post hoc test. Group RLP,
rituximab + low-dose IVIG + plasmapheresis; group BLP, borte-
zomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib









































































Figure 3: Proteinuria before, during, and after treatment of
antibody-mediated rejection of all patients with a functioning graft
at each time point. Differences between groups were calculated by
Kruskal-Wallis test withDunn-Bonferroni post hoc test. Group RLP,
rituximab + low-dose IVIG + plasmapheresis; group BLP, borte-
zomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib
+ high-dose IVIG + plasmapheresis. ∗𝑝 = 0.049 versus group RLP
and group BLP.
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(𝑛 = 11) 𝑝
Number of HLA mismatches per patient (mean ± SD)
Class I (A, B) 2.2 ± 1.2 2.0 ± 1.3 2.7 ± 0.9 n.s.
Class II (DR, DQ) 1.7 ± 0.9 2.5 ± 1.1 2.0 ± 1.2 n.s.
HLA antibody panel reactivity (% PRA) at diagnosis (mean ± SD)
Class I 85 ± 14 50 ± 30 41 ± 20 n.s.
Class II 66 ± 20 63 ± 19 63 ± 28 n.s.
DSAmax MFI (mean ± SD)
At diagnosis 8539 ± 5478 9747 ± 8363 8467 ± 6876 n.s.
After treatment 8196 ± 5425 7891 ± 6475 5221 ± 4711a n.s.
DSAsum MFI (mean ± SD)
At diagnosis 11,235 ± 10,116 12,937 ± 11,196 10,657 ± 8973 n.s.
After treatment 12,900 ± 11,018 12,653 ± 12,744 5587 ± 4509b n.s.
Patients with a decrease of [% (count)]
DSAmax 33% (4) 72% (8) 82% (9) 0.036 (group BHPversus RLP)
DSAmax < 500 MFI 8% (1) 9% (1) 18% (2) n.s.
DSAsum 33% (4) 72% (8) 72% (8) n.s.
Group RLP, rituximab + low-dose IVIG + plasmapheresis; group BLP, bortezomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose
IVIG+ plasmapheresis.DSAmax, donor-specificHLA antibody showing the highestmean fluorescence intensity (MFI) at time of diagnosis. n.s., not significant.
a𝑝 = 0.01 in comparison to before treatment. b𝑝 = 0.04 in comparison to before treatment.
of groups BLP and BHPwas lower as compared to group RLP
(50% and 41% versus 85%, 𝑝 = 0.07). Concerning the level of
DSAmax and DSAsum before treatment as indicated byMFI,
there was no significant difference between groups. Inter-
estingly, following treatment, DSAmax and DSAsum could
be decreased significantly as compared to the pretreatment
status in group BHP, but not in the other two groups. The
BHP treatment scheme was statistically more efficient in the
decrease of DSAmax MFI levels than the RLP scheme [9/11
(82%) versus 4/12 (33%), 𝑝 = 0.04]. In all three groups, there
were a few patients with a posttreatment DSAmax level below
500 MFI.
The observed side effects during the first year after
treatment are shown in Table 3. The most frequent side
effects were haemoglobin reduction (94%), thrombocytope-
nia (76%), and leukopenia (59%). We observed two cases
of grade IV leukopenia in the RLP group and four cases
of grade III leukopenia, two of which in the RLP group
and two in the BLP group. In the BLP group there were
two cases of grade III thrombocytopenia in patients with
preexisting thrombocytopenia. All episodes of leukopenia
and thrombocytopenia were spontaneously reversible. Dur-
ing episodes of thrombocytopenia no bleeding events were
evident. Amild to moderate (grade I-II) increase of transam-
inase levels occurred in 41% of all patients. Altogether 35
episodes of infection were observed in 16/34 (47%) patients.
No difference between groups was found regarding the
frequency of infections, neither in general nor with respect to
specific infections. Gastrointestinal side effects were observed
more frequently in patients, who received bortezomib. In
the BHP group significantly more patients suffered from
diarrhea as compared to the RLP group (64% versus 8%,
𝑝 = 0.009). Reversible peripheral sensory neuropathy
(grade I-II) occurred in two patients of the BHP group. One
patient in each group experienced a mild allergic reaction
during the IVIG infusion. These events were successfully
treated with antihistamines and prednisolone. The number
of hospitalizations as well as the number of hospitalized
patients was not significantly different between groups. In
two patients of group BHP a nonmelanoma skin cancer was
diagnosed and successfully treated by local excision.
To correct for any covariate with a potential impact on
allograft outcome following ABMR treatment, we performed
a Cox proportional hazard analysis with clinical, immuno-
logical, and therapeutic covariates as summarized in Table 4.
Based on the univariate analysis we identified an impaired
allograft function (i.e., eGFR < 30mL/min/1.73m2) at the
time of ABMR diagnosis as well as treatment with rituximab,
bortezomib, and high-dose IVIG as the only statistically
significant predictors for allograft survival following ABMR
treatment. Impaired graft function at diagnosis and ABMR
treatment by rituximab were identified as risk factors for
subsequent allograft survival. On the contrary, bortezomib
and high-dose IVIG revealed a beneficial effect. Subsequent
multivariate analysis was performed using impaired graft
function at diagnosis and the treatment options rituximab,
bortezomib, and IVIG dose as combined covariates. Taken
together, impaired allograft function contributed signifi-
cantly as a risk factor to the regression model (HR = 3.26,
95% CI: 1.29–8.24, 𝑝 = 0.01) and bortezomib plus high-
dose IVIG treatment revealed the strongest beneficial effect
on allograft survival following ABMR treatment (HR = 0.21,
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(𝑛 = 11) 𝑝
Haemoglobin reduction: baseline – nadir (mg/dL) 2.1 ± 1.5 2.3 ± 1.8 2.8 ± 1.3 n.s.
Thrombocytopenia (patients) 9 10 7 n.s.
Leukopenia (patients) 8 6 6 n.s.
Increase of serum transaminase levels (patients) 6 5 3 n.s.
Infections (events/patients) 14/7 12/7 9/2 n.s./n.s.
Urinary tract infection 7/4 2/1 7/1 n.s./n.s.
Otitis media 2/2 0/0 0/0 n.s./n.s.
Tonsillitis 0/0 1/1 1/1 n.s./n.s.
Pneumonia 1/1 0/0 0/0 n.s./n.s.
Enterocolitis 4/4 4/4 0/0 n.s./n.s.
Central venous catheter infection 0/0 2/2 0/0 n.s./n.s.
CMV reactivation 0/0 2/2 1/1 n.s./n.s.
Fever of unknown origin 0/0 1/1 0/0 n.s./n.s.
Nausea (patients) 0 0 2 n.s.
Vomiting (patients) 0 0 2 n.s.
Diarrhea (patients) 1 2 7 0.009 (RLP versus BHP)
Peripheral sensory neuropathy (patients) 0 0 2 n.s.
Allergic reaction to IVIG (patients) 1 1 1 n.s.
Hospitalizations (events/patients) 16/8 9/7 10/5 n.s./n.s.
Nonmelanoma skin cancer (patients) 0 0 2 n.s.
Adverse events during the first year after treatment are shown except for malignancies, where the whole follow-up period was considered. Note. Some
patients suffered frommore than one gastrointestinal adverse event (nausea, vomiting, or diarrhea) simultaneously. Group RLP, rituximab + low-dose IVIG +
plasmapheresis; group BLP, bortezomib + low-dose IVIG + plasmapheresis; group BHP, bortezomib + high-dose IVIG + plasmapheresis.
Table 4: Univariate and multivariate cox regression analysis of clinical, immunological, and therapeutic covariates to predict allograft loss
following ABMR treatment. Covariates were only considered for the multivariate cox regression model if statistically significant in the
univariate analysis.
HR 95% CI 𝑝
Univariate
Retransplantation 1.70 0.66–4.37 0.27
Induction therapy by IL-2R antibody 0.82 0.31–2.13 0.68
Early ABMR 0.97 0.38–2.47 0.95
eGFR < 30mL/min/1.73m2 at ABMR diagnosis 2.67 1.07–6.63 0.03
Chronic glomerulopathy (cg) score ≥ 1 at ABMR diagnosis 1.69 0.71–4.01 0.23
DSA class I 0.65 0.28–1.50 0.31
DSA class II 0.82 0.30–2.24 0.70
DSA class I + II 0.77 0.32–1.88 0.57
DSAmax > 10,000 MFI 1.57 0.69–3.57 0.28
Everolimus-based maintenance immunosuppression 0.52 0.07–3.94 0.52
ABMR treatment by rituximab 2.74 1.16–6.47 0.02
ABMR treatment by bortezomib 0.37 0.15–0.86 0.02
ABMR treatment by high-dose IVIG 0.34 0.13–0.93 0.04
Multivariate
ABMR treatment by rituximab + low-dose IVIG (RLP) 1.00 n.a. n.a
ABMR treatment by bortezomib + low-dose IVIG (BLP) 0.58 0.22–1.52 0.27
ABMR treatment by bortezomib + high-dose IVIG (BHP) 0.21 0.07–0.62 0.005
eGFR < 30mL/min/1.73m2 at ABMR diagnosis 3.26 1.29–8.24 0.01
DSA, donor-specific HLA antibody(ies), HR, hazard ratio, MFI, mean fluorescence intensity, n.a., not applicable, 95%CI, confidence interval 95%.
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95% CI: 0.07–0.62, 𝑝 = 0.005) as compared to rituximab plus
low-dose IVIG.
4. Discussion
Theexisting literature on the treatment ofABMR is character-
ized by a marked heterogeneity concerning the definition of
ABMR as well as the applied treatment protocols [5]. Notably,
a considerable number of the available studies was performed
before the introduction of a pathology-based definition for
ABMR in 2003 [14]. At that time, various and nowadays
outdated criteria to diagnose ABMR were oftentimes used.
In addition, new therapeutics more specifically targeting B
cell-mediated immune response have become available. The
efficacy of these substances as well as their combination with
established treatment protocols has not yet been studied suf-
ficiently. A recent randomized study could not demonstrate
a benefit of rituximab compared to placebo [15]. Therefore,
current evidence for the treatment of ABMR is anything else
but satisfactory.
To date, IVIG preparations are widely used for treatment
of ABMR [4]. Yet, it is not known, whether high-dose
IVIG treatment is advisable in combination with modern
antihumoral therapeutics such as bortezomib. Here, we
addressed this important question by comparing the efficacy
and safety of high-dose IVIG treatment in combination with
bortezomib and PPH in 11 consecutive patients with biopsy-
proven ABMR (group BHP) with a group of 12 patients
treated with low-dose IVIG together with a fixed dose of
rituximab and PPH (group RLP) and with a group of 11
patients treated with low-dose IVIG together bortezomib
and PPH (group BLP). Group RLP and group BLP have
already been partially described in our previous study [7].
Extending the results of this study group RLP now comprises
three additional patients, that is, altogether 12 patients, and
the median observation time of the present study has been
markedly prolonged as compared to our previous study
(group RLP: 101 versus 18 months, group BLP: 88 versus 18
months). Notably, themedian observation time exceeded five
years in all groups. The three groups presented here were
comparable regarding the underlying patient characteristics,
renal function, and renal pathology at diagnosis except for the
transplant glomerulopathy (cg) score, whichwas significantly
higher in group BLP as compared to group BHP.
Our results indicate that treatment with bortezomib in
combination with high-dose IVIG and PPH (group BHP)
is statistically superior as compared to treatment with rit-
uximab, low-dose IVIG, and PPH (group RLP). In addi-
tion, high-dose IVIG with bortezomib and PPH seemed to
be advantageous as compared to low-dose IVIG with an
identical regimen comprising bortezomib and PPH. Both
the change from rituximab-based treatment to bortezomib-
based treatment and the increase of the IVIGdose froma low-
dose to a high-dose regimen resulted in a stepwise improve-
ment of graft survival and graft function. The observed
reduction of DSA following treatment in the BHP group
but to a lower extent in both other groups reflects the
clinical course and is in concordance with the literature.
Terasaki and colleagues demonstrated that a decrease inHLA
antibody levels can be used as a surrogate marker for the
efficacy of an antirejection treatment and directly correlates
with superior allograft survival [16]. Therefore, our results
confirm and extend our previous observations [7] inasmuch
as bortezomib-based treatment proved to be superior to
rituximab-based treatment and that the addition of high-dose
IVIG further increased graft survival. Our findings are in line
with the results from the randomized RITUX-ERAH trial
[15], which demonstrated no statistically significant effects
of rituximab for the treatment of ABMR. Our results also
suggest that high-dose IVIG seems to be advisable in the
presence of modern antihumoral therapeutics such as borte-
zomib. This conclusion is supported by experimental data
showing that only a small proportion of IgG in the available
IVIG preparations is responsible for the immunosuppressive
effect [8, 9]. Therefore, the amount of applied IVIG seems to
be crucial for the success of treatment.
Theoretically, it would have been interesting to investigate
a group of patients treated with rituximab, PPH, and high-
dose IVIG, in order to further elucidate the efficacy of ritux-
imab and high-dose IVIG treatment. However, in our previ-
ous study [7] we observed a clear trend towards an improved
graft survival in patients, who received a bortezomib-based
treatment over a rituximab-based treatment, so that we
deliberately decided to treat all upcoming patients with a
bortezomib-based protocol and refrained from further trials
on rituximab-based treatment in order not to expose patients
to a (in our opinion) potentially higher risk of graft loss.
First reports on the effects of IVIG in the context of
renal transplantation have been published 20–30 years ago.
In 1984, Steiner et al. investigated the impact of prophy-
lactic IVIG administration on the rate of infection in a
prospective randomized trial [17]. Because the proportion
of patients discharged with a functioning graft was lower in
the treatment group, the authors concluded that prophylactic
administration of IVIG is “not only useless but probably
dangerous.” About one decade later, Peraldi et al. showed
that early high-dose IVIG treatment (2 g/kg) following renal
retransplantation improved 5-year graft survival [18]. One of
the first reports demonstrating that high-dose IVIG (2 g/kg)
may be effective in the treatment of ABMR following kidney
transplantation was published by Jordan et al. in 1998 [19]. In
2001, Casadei and colleagues observed that high-dose IVIG
treatment (3.5 g/kg) was equally effective in the treatment
of steroid-resistant rejection as OKT3 [20]. At the same
time, Luke and colleagues also found that high-dose IVIG
(2 g/kg) was effective to reverse steroid- or antilymphocyte
antibody-resistant rejection [21]. Importantly, a consistent
definition of ABMR based on pathological findings and the
presence of circulating DSA was not introduced into the
Banff classification until 2003 [14]. Consequently, studies
performed before 2003 must be regarded with caution. In the
more recent era, Lefaucheur et al. reported that treatment of
ABMR with high-dose IVIG alone (2 g/kg ×4) was inferior
to a combination of high-dose IVIG, PPH, and rituximab,
indicating that IVIG alone, even if applied in very high doses,
is not sufficient to treat ABMR [22]. In 2014, Cooper et al.
showed that high-dose IVIG alone (5 g/kg) caused a modest
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DSA reduction, especially concerning class I DSA in patients
with previous acute ABMR [23].
The effectiveness of IVIG therapy on circulating HLAab
has also been investigated in various studies on pretransplant
desensitization. In 1993, Glotz et al. described that pretrans-
plant administration of high-dose IVIG (1.6 g/kg) suppresses
HLAab formation [24]. More than ten years later, Jordan
et al. showed that high-dose IVIG treatment (2 g/kg ×4)
reduced PRA levels [25]. In 2006, Stegall et al. observed
that high-dose IVIG treatment (2 g/kg) decreased DSA titers
[26]. Vo and colleagues reported in 2008 that treatment with
high-dose IVIG (2 g/kg ×2) and rituximab (375mg/m2×2)
reduced PRA levels from 77% to 44% [27]. Recently, the
same group compared desensitization with high-dose IVIG
(2 g/kg ×2) plus rituximab (1 g) to high-dose IVIG (2 g/kg
×2) plus placebo in a randomized clinical study [28]. Patients
received an additional dose of IVIG at transplantation plus
an additional dose of rituximab or placebo at six months
after transplant. Following transplantation of 13 patients, the
study was halted and unblinded because of three episodes
of ABMR. All episodes had occurred in the placebo group
(3/7) indicating that high-dose IVIG alone did not sufficiently
prevent ABMR. Notably, 1/6 patients in the rituximab group
died at 12 months after transplantation from aNocardia brain
abscess.
In group BLP, two patients received maintenance immu-
nosuppression including everolimus following diagnosis.
One of these patients returned to maintenance hemodialysis
at 6 months after diagnosis; in the other patient serum creati-
nine at 88months after diagnosis is stable at 2.4mg/dL. In this
patient we did not reinitiate calcineurin-inhibitor treatment
because of a history of cyclosporine A-induced hemolytic
uremic syndrome soon after transplantation. Notably, we
were not yet aware of the fact that everolimus-based immuno-
suppression is associated with an increased risk for the
development of DSA and ABMR in 2009 [29]. In addition,
a higher cg score was observed in patients of group BLP as
compared to group BHP. This might be important, as Billing
et al. showed that the degree of transplant glomerulopathy
is associated with the response to treatment [30]. Therefore,
we included maintenance immunosuppression and cg scores
at the time of ABMR diagnosis as covariates in our Cox
proportional hazard analysis but could not find a statistically
significant impact on allograft outcome.
Taken together, our results demonstrate that graft sur-
vival of patients with a diagnosis of ABMR following renal
transplantation improved during the past years alongwith the
introduction of bortezomib and high-dose IVIG treatment
resulting in a 5-year graft survival of about 50% following
diagnosis. In conclusion, the use of high-dose IVIG in com-
bination with a bortezomib-based treatment regimen seems
to be useful, especially when compared to a historical group
of patients treated with low-dose IVIG, PPH, and rituximab.
The degree of DSA reduction in group BHP supports this
conclusion and may be used as biomarker for the efficacy of
treatment. In our view, stepwise controlled modifications of
the established treatment protocols are helpful to gradually
improve the prognosis following a diagnosis of ABMR. The
main limitation of our study is the fact that it is a retrospective
study with a limited number of patients comprising episodes
of early and late ABMR and comparing cohorts treated at
different time periods that differ in some important variables.
Therefore, the results must be interpreted with caution, and
further studies are necessary to confirm our findings. In
future, IVIG preparations containing a higher proportion of
Fc fragments with terminal sialic acid residues may be even
more effective. Until such preparations will be available, the




DSA: Donor-specific HLA antibodies
DSAmax: DSA showing the highest MFI at the time
of ABMR diagnosis
DSAsum: MFI sum of all DSA exceeding 500 MFI
HLAab: HLA antibody(ies)
IVIG: Intravenous immunoglobulins
MFI: Mean fluorescence intensity
PPH: Plasmapheresis.
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